Results 271 to 280 of about 165,400 (311)

Clinical characteristics and risk factors of severe bocavirus‐positive pneumonia in children and a literature review

open access: yesPediatric Discovery, EarlyView.
The study explored the clinical characteristics and risk factors of HBoV‐positive severe pneumonia in children. These findings indicate that HBoV can be identified in respiratory samples from children with severe pneumonia, denoting its role as a viral pathogen in hospitalized children with this condition.
Jing Liao   +6 more
wiley   +1 more source

Multispacecraft Observations of the 2024 September 9 Backside Solar Eruption That Resulted in a Sustained Gamma Ray Emission Event. [PDF]

open access: yesSol Phys
Gopalswamy N   +8 more
europepmc   +1 more source

“I'd rather be in pain than be patronized.” A qualitative study of health care experiences of persons with disabilities

open access: yesPM&R, EarlyView.
Abstract Background Prior research shows that persons with disabilities (PWD) frequently receive inadequate health care and that physicians are uncomfortable caring for patients with disabilities, both of which may be attributed to the lack of disability education in medical training.
Jessica A. Prokup   +5 more
wiley   +1 more source

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Cabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration‐resistant prostate cancer (CRPC), yet it is typically reserved for post‐docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.
Taketo Kawai   +13 more
wiley   +1 more source

A fair machine learning model to predict flares of systemic lupus erythematosus. [PDF]

open access: yesJAMIA Open
Li Y   +10 more
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani   +5 more
wiley   +1 more source

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy